Public health officials seem unaware of the likely role of Covid-19 vaccines in accelerating the development of stealth-adapted coronaviruses. In fact, they have not yet accepted the existence of widespread human infections with viruses derived from stealth-adapted monkeys. These viruses were inadvertently introduced to humans from polio vaccines. This occurred as a consequence of the use of polio vaccines grown in cultured kidney cells from monkeys infected with cytomegalovirus.
One mistaken assumption is that current COVID-19 vaccines provide immunity comparable to natural infections. This is clearly not so. First of all, the vaccine is administered by intramuscular injections, while natural infections occur through the respiratory mucosa. Intramuscular injections are not particularly effective in stimulating the development of mucosal immunoglobulin A (IgA) antibodies or resident cytotoxic T lymphocytes (CTLs). The reduced level of vaccine-induced mucosal immunity means that following exposure to the SARS-CoV-2 virus, a proportion of vaccinated people are likely to acquire a persistent subclinical infection that is limited to the superficial respiratory mucosa. Public Health authorities allude to this possibility by insisting that those who are immunized must continue to wear masks. However, persistent low-level infections will provide the opportunity for variants of the virus to emerge. Some of these will be more infectious, while others will be better able to evade the immunity caused by the vaccine and therefore spread further throughout the body.
The second big difference between the vaccine and natural infection is that the FDA allows the use of only one component of the virus in the vaccine, namely the spike protein. It is much easier to modify, or even eliminate, a single component virus than it is for simultaneous changes to occur in multiple antigens targeted by immunity against natural infections. Removal of the spike protein is possible as coronaviruses have other means of entering cells. The virus can then more easily undergo changes in the remaining genes that code for the relatively few components of the virus that are normally targeted by cellular immunity.
The persistence of subclinical infections due to the relative lack of mucosal immunity achieved by intramuscular injections and the systemic immune response restricted only to the spike protein, may lead more rapidly than natural infection to the formation of stealth-adapted coronaviruses. A corollary to this premise is that the English, South African, and Brazilian variants likely originated from individual participants in the Covid-19 vaccine trials conducted in each of the countries. With wider use of the vaccine, many more variants are expected, including stealth-adapted coronaviruses.
Stealth adaptation has another very worrying feature. It is the incorporation of additional genetic sequences that is probably required for the virus to regain infectivity. The added sequences can come from the cellular genome and from the genomes of other microbes. This has allowed, for example, stealth-adapted viruses derived from the polio vaccine to bring monkey cell sequences to humans.
The brain is particularly susceptible to symptomatic diseases caused by stealth-adapted viruses. These viruses can be cultured from patients with chronic fatigue syndrome (CFS) and also from children with autism. Long Covid syndrome has many clinical features in common with CFS. Until proven otherwise, Long Covid syndrome should be considered a viral illness with the potential for person-to-person transmission, including during pregnancy. It is essential to start culturing blood samples from patients with Long Covid syndrome and sequencing the resulting viruses.
Although the cellular immune system will not normally engage with stealth-adapted viruses, they can still be suppressed through the alternative cellular energy (ACE) pathway. This pathway likely preceded photosynthesis in plants and all life forms obtaining energy from the metabolism of food. In humans and animals, the brain is probably the main recipient of life energy for the ACE pathway. The attracted energy is then transferred to the body fluids where it is expressed as further kinetic activity. The energy is called KELEA, an abbreviation for Kinetic Energy Limiting Electrostatic Attraction. KELEA can also be added to water, which is then called KELEA excellent water. Portable bags containing this water and inhalation of nebulized mists of the water are being evaluated as simple means of improving the ACE pathway. These approaches can apparently suppress both conventional and stealthy viral diseases.
A more detailed discussion of these topics can be found in the book “Stealth Adapted Viruses; Alternative Cellular Energy (ACE) & KELEA Activatedf Water”. Supporting information is also available at the following sites:
https://zenodo.org/record/4489960#.YBizzS2cbEY
https://zenodo.org/record/4489960#.YBmpCC1h1N1